The Schall Law Firm Is Initiating An Investigation Into Accusations Against Medifast, Inc. And Urges Investor Engagement
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Announces A Probe Into Allegations Against Medifast, Inc. And Encourages Investor Involvement
LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Declares An Investigation Into Claims Against Medifast, Inc. And Invites Investor Participation
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Announces An Inquiry Into Allegations Against Medifast, Inc. And Encourages Investor Engagement
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Proclaims an Investigation into Accusations Against Medifast, Inc. and Urges Investor Communication
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
MED INVESTIGATION PROGRESS UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION PROGRESS UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION PROGRESS ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION PROGRESS REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zacks Research Weighs in on Medifast, Inc.’s Q2 2024 Earnings (NYSE:MED)
Medifast, Inc. (NYSE:MED – Free Report) – Stock analysts at Zacks Research issued their Q2 2024 earnings per share estimates for Medifast in a report issued on Thursday, May 16th. Zacks Research analyst A. Mohta expects that the specialty retailer will earn $0.32 per share for the quarter. The consensus estimate for Medifast’s current full-year earnings is $0.95 per share. Zacks Research also issued estimates for Medifast’s Q3 2024 earnings at $0.14 EPS, Q4 2024 earnings at $0.21 EPS, FY2024 earnings at $1.33 EPS, Q1 2025 earnings at $0.58 EPS, Q2 2025 earnings at $0.64 EPS, Q3 2025 earnings at $0.53 EPS, Q4 2025 earnings at $0.62 EPS, FY2025 earnings at $2.37 EPS, Q1 2026 earnings at $0.89 EPS and FY2026 earnings at $3.16 EPS. Medifast (NYSE:MED – Get Free Report) last posted its quarterly earnings results on Monday, April 29th. The specialty retailer reported $0.66 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.12). Medifast had a return on equity of 36.64% and a net margin of 7.55%. The company had revenue of $174.74 million during the quarter, compared to the consensus estimate of $168.90 million. During the same period in the previous year, the business earned $3.67 earnings per share. Medifast’s revenue was down 49.9% on a year-over-year basis. MED has been the topic of a number of other research reports. DA Davidson lowered their price objective on Medifast from $40.00 to $25.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 30th. TheStreet downgraded Medifast from a “c” rating to a “d+” rating in a research report on Wednesday, February 21st. View Our Latest Analysis on Medifast Medifast Stock Performance Shares of MED stock opened at $25.00 on Monday. Medifast has a 52-week low of $24.58 and a 52-week high of $109.52. The company has a market capitalization of $273.50 million, a PE ratio of 4.03 and a beta of 1.19. The business’s fifty day moving average is $32.08 and its 200 day moving average is $49.90. Insider Buying and Selling at Medifast In other news, Director Scott Schlackman sold 4,053 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $39.44, for a total transaction of $159,850.32. Following the transaction, the director now directly owns 7,785 shares of the company’s stock, valued at $307,040.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.06% of the company’s stock. Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently modified their holdings of MED. Bank of New York Mellon Corp grew its stake in shares of Medifast by 2.1% during the third quarter. Bank of New York Mellon Corp now owns 194,369 shares of the specialty retailer’s stock valued at $14,549,000 after buying an additional 4,005 shares during the last quarter. TD Asset Management Inc grew its stake in shares of Medifast by 35.8% during the third quarter. TD Asset Management Inc now owns 9,100 shares of the specialty retailer’s stock valued at $681,000 after buying an additional 2,400 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Medifast by 32.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 8,984 shares of the specialty retailer’s stock worth $672,000 after purchasing an additional 2,188 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Medifast by 112.6% in the third quarter. Nisa Investment Advisors LLC now owns 7,281 shares of the specialty retailer’s stock worth $545,000 after purchasing an additional 3,857 shares during the last quarter. Finally, Olympiad Research LP bought a new stake in shares of Medifast in the third quarter worth about $208,000. 95.51% of the stock is owned by institutional investors. About Medifast (Get Free Report) Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. Read More Five stocks we like better than Medifast Why Understanding Call Option Volume is Essential to Successful Options Trading MarketBeat Week in Review – 5/13 – 5/17 CD Calculator: Certificate of Deposit Calculator Take-Two Interactive Software Offers 2nd Chance for Investors Canadian Penny Stocks: Can They Make You Rich? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Medifast, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
